ALC News and Press, Alcon Inc. From 11/15/22

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Last week the markets saw their best single-session gain in more than two years as investors celebrated the favorable Consumer Price Index ( CPI ) reading. And then today’s Producer Price Index (PPI) had Wall Stree...

Third quarter 2022 sales of $2.1 billion, up 2%, or 9% constant currency (cc) Third quarter 2022 earnings were $0.23 per diluted share; core earnings of $0.50 per diluted share, down 7%, or up 14% cc Updated 2022 outlook reflects strong sales growth and operational l...

Alcon ( NYSE: ALC ) is scheduled to announce Q3 earnings results on Tuesday, November 15th, after market close. The consensus EPS Estimate is $0.49 (-9.3% Y/Y) and the consensus Revenue Estimate is $2.13B (+2.4% Y/Y). Over the last 2 years, ALC has beaten EPS estimat...

Summary Several long-standing biopharmaceutical holdings drove performance. An unprecedented set of global challenges makes it more important than ever to own cash-generative businesses with strong balance sheets that can take advantage of dislocations in the market and the econom...

Summary Weakness in the Strategy’s consumer discretionary and technology names and underweights to several outperforming mega cap growth stocks weighed on performance relative to the benchmark. Weakness in the Strategy’s consumer discretionary and technology names an...

Highlighting latest clinical findings, including comparative efficacy for ocular itch relief between Pataday Once Daily Relief Extra Strength and an oral antihistamine Forthcoming innovations in eye care to be previewed, including TOTAL30 for Astigmatism TOTAL po...

Founded in 1945 and based in Switzerland, Alcon AG (ALC) is a global provider of ophthalmic surgery and vision care products; previously a subsidiary of Novartis AG (NVS), Alcon became an independent company in April, 2019, recalls Jasper Hellweg, an analyst with Argus Research. For further...

Clareon Toric, a glistening-free * toric intraocular lens with exceptional clarity and unrivaled stability, is rolling out across select practices in the U.S. 1-5 Alcon digital innovations, including the newly available Fidelis Virtual Reality Ophthalmic Surgical Sim...

Summary A high level of restructuring is occurring with the Healthcare industry’s largest constituents. Most restructuring is taking the form of splits or spin-offs, but not all incidences look beneficial. This article will summarize coming transactions and provide comm...

Summary Alcon has continued in a downtrend since September 2021 with persistent mean reversion activity across this time. With FY22 guidance narrowed and macro-headwinds prevailing, forward-looking multiples are less attractive to peers. We see a value gap to the downside in A...